Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma

Gupta, Nidhi; Kumar, Raman; Seth, Tulika; Garg, Bhavuk; Sati, Hem Chandra; Sharma, Alpana

doi:10.1007/s00432-019-02896-1

Cited by 34 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, they are highly specific, and it has been shown that miRNA expression profiles differ between cancer types according to diagnosis and the developmental stage of the tumor, with a greater resolution than traditional gene expression analysis [19]. Secondly, unlike other RNA classes, miRNAs are remarkably stable and therefore can be robustly measured not only in biological fluids but also from routinely prepared formalin-fixed paraffin-embedded (FFPE) material [14].…”

Section: Discussionmentioning

confidence: 99%

“…Diaz-Beya et al reported that high miR-3151 expression was commonly found in AML patients and obtained shorter disease-free, OS, lower CR rate and higher cumulative incidence of relapse compared with low expressers [11]. Several studies have reported that miR-203 functions as a tumor suppressor in various cancers, including leukemia, esophageal cancer, and breast cancer [12,13], inhibiting cancer cell proliferation [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia

Guo¹

2019

Bioengineered

View full text Add to dashboard Cite

This study aimed to detect serum miR-203 expression levels in AML and explore its potential clinical significance. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to measure the serum miR-203 levels in 134 patients with AML and 70 healthy controls. The results demonstrated that serum miR-203 expression was significantly reduced in AML patients compared with healthy controls. Receiver operating characteristic curve (ROC) analysis revealed miR-203 could distinguish AML cases from normal controls. Low serum miR-203 levels were associated with worse clinical features, as well as poorer overall survival and relapse free survival of AML patients. Moreover, multivariate analysis confirmed low serum miR-203 expression to be an independent unfavorable prognostic predictor for AML. The bioinformatics analysis showed that the downstream genes and pathways of miR-203 was closely associated with tumorigenesis. Downregulation of miR-203 in AML cell lines upregulated the expression levels of oncogenic promoters such as CREB1, SRC and HDAC1. Thus, these findings demonstrated that serum miR-203 might be a promising biomarker for the diagnosis and prognosis of AML. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia

Guo¹

2019

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Several studies had analyzed the accuracy of circulating miRNAs in diagnosing MM. For instance, Cai [33] and Nidhi [31] et al pointed out that the sensitivity and speci city of miR-497 and miR-199 in diagnosing MM were 86.0% and 96.0%, 80.0% and 80.0%, respectively. According to reports by Yoshizawa [19] , the sensitivity and speci city of miRNA-92a were 91.9% and 99.1%, respectively, and its diagnostic accuracy was satisfactory.…”

Section: Discussionmentioning

confidence: 99%

“…With the rise of miRNAs in recent years, many studies have shown that the accuracy of circulating miRNAs in the early diagnosis of MM is satisfactory but inconsistent [18][19][20][21] . This may be caused by factors such as different detection technologies, platforms, standards, and insu cient clinical samples.…”

Section: MMmentioning

confidence: 99%

Potential Diagnostic Value of Circulating miRNA for Multiple Myeloma: A Meta-Analysis.

Zhang

Gao

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second incurable hematological malignancy. In recent years, due to the rise of microRNA (miRNA), many scholars have participated in the study of its value in the diagnosis of MM, and have obtained good but inconsistent results. Therefore, in order to determine the role of miRNA in the early diagnosis of MM, we searched for related studies including PubMed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI) and Wanfang Database as of July 20, 2020 to conduct this meta-analysis. To improve the accuracy, the quality assessment of Diagnostic Accuracy Study 2 (QUADAS-2) was used. We also applied random effects models to summarize sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve (AUC) to measure diagnostic values, and subgroup analysis used to discover potential sources of heterogeneity. Finally, we collected 32 studies from 15 articles that included a total of 2053 MM patients and 1118 healthy controls. The overall sensitivity, specificity, PLR, NLR, DOR and AUC were 0.81, 0.85, 5.5, 0.22, 25 and 0.90, respectively. Subgroup analysis shows that the down-regulation of microRNA clusters with larger samples size of plasma type could carry out a better diagnostic accuracy of MM patients. In addition, publication bias was not found. In conclusion, circulating miRNA could be a potential non-invasive biomarker for early diagnosis of MM. However, multi-center, more rigorous, and larger-scale studies are needed to verify our conclusions.

show abstract

“…A pattern of five circulating miRNAs was significantly reduced in patients with relapsed/refractory MM and poor responders after treatment with lenalidomide plus low-dose dexamethasone [198]. A relative lower expression of miR-143, miR-144, miR-199 and miR-203 in both BM supernatant fluid and serum of MM patients was found as compared with healthy controls; in these patients, levels of the proteoglycan VCAN positively, whereas miRNAs negatively correlated with the severity of disease [199].…”

Section: Circulating Ncrnas In Pc Dyscrasiasmentioning

confidence: 91%

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Morelli

Gullà

Rocca

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat. The discovery and subsequent characterization of non-coding transcripts, which include several members with diverse length and mode of action, has unraveled novel mechanisms of gene expression regulation often malfunctioning in cancer. Increasing evidence indicates that such non-coding molecules also feature in the pathobiology of PC dyscrasias, where they are endowed with strong therapeutic and/or prognostic potential. In this review, we aim to summarize the most relevant findings on the biological and clinical features of the non-coding RNA landscape of malignant PCs, with major focus on multiple myeloma. The most relevant classes of non-coding RNAs will be examined, along with the mechanisms accounting for their dysregulation and the recent strategies used for their targeting in PC dyscrasias. It is hoped these insights may lead to clinical applications of non-coding RNA molecules as biomarkers or therapeutic targets/agents in the near future.

show abstract

Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma

Cited by 34 publications

References 28 publications

RETRACTED ARTICLE: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia

RETRACTED ARTICLE: Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia

Potential Diagnostic Value of Circulating miRNA for Multiple Myeloma: A Meta-Analysis.

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias

Contact Info

Product

Resources

About